NCT05260411 - A Study to Evaluate the Efficacy and Safety of AK102 Q6W in Patients With Hyperlipidemia | Biotech Hunter

Enrollment

246

Participants

Timeline

Start Date

January 26, 2022

Primary Completion Date

December 19, 2022

Study Completion Date

December 19, 2022

Conditions

Hyperlipidemia

Interventions

BIOLOGICAL

AK102

Administered AK102 450 mg by subcutaneous injection every 6 weeks Drug: Statins and/or Ezetimibe lipid-lowering therapies

BIOLOGICAL

AK102

Administered AK102 600 mg by subcutaneous injection every 6 weeks Drug: Statins and/or Ezetimibe lipid-lowering therapies

DRUG

Placebo

Administered placebo by subcutaneous injection every 6 weeks Drug: Statins and/or Ezetimibe lipid-lowering therapies

Trial Locations (2)

The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou

Zhongshan Hospital, Fudan Hospital, Shanghai